(Total Views: 281)
Posted On: 01/29/2021 2:10:23 PM
Post# of 36566
I would be disappointed to have missed out on the opportunity to make the public aware of the companies progress. However I would love a surprise.
From the PR on 12/31:
With an impending IND submission for Phase I and II human clinical trials to evaluate safety and
immunogenicity of the Ii-Key vaccine, NGIO is exploring additional opportunities to deploy the
targeted Ii-Key COVID-19 vaccine as a universal booster for RNA, DNA, and inactivated virus
vaccines that contain the entire spike protein and have the potential to elicit off-target and overactive immune responses.
You might want to add this site to your favorites. Studies get listed here:
https://clinicaltrials.gov/ct2/home
From the PR on 12/31:
With an impending IND submission for Phase I and II human clinical trials to evaluate safety and
immunogenicity of the Ii-Key vaccine, NGIO is exploring additional opportunities to deploy the
targeted Ii-Key COVID-19 vaccine as a universal booster for RNA, DNA, and inactivated virus
vaccines that contain the entire spike protein and have the potential to elicit off-target and overactive immune responses.
You might want to add this site to your favorites. Studies get listed here:
https://clinicaltrials.gov/ct2/home
(1)
(0)
